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Abstract
Background. Despite the progress in the treatment of heart failure with reduced ejection fraction (HFrEF), 
the prognosis remains unfavorable.
Objectives. To evaluate the effectiveness, tolerance and safety after one-year follow-up of Polish patients 
with stable chronic HFrEF treated with sacubitril/valsartan.
Material and methods. This was an observational multicenter study conducted in 3 centers (Kraków, 
Łódź and Warszawa) specializing in heart failure (HF). We enrolled 89 HFrEF patients (aged 59.3 ±13.5 years, 
82% males) in NYHA class II–IV (ambulatory). Clinical, laboratory and echocardiographic parameters were 
evaluated at baseline and after a one-year follow-up. The composite endpoint was defined as death or urgent 
HF hospitalization.
Results. After 1 year, 80% of patients used 50% or more of the target dose of sacubitril/valsartan. After 
a year of treatment, there were significant improvements of HF symptoms, N-terminal prohormone B-type 
natriuretic peptide (NT proBNP), ejection fraction (EF), and distance in six-minute walk test (6MWP) (all 
p < 0.001). Patients treated with the highest dose of sacubitril/valsartan exhibited the greatest benefits. 
The safety profile was favorable and consistent with that previously reported; however, therapy discontinu-
ation due to side effects occurred in 11% of patients. The independent predictors for composite endpoint 
(n = 24, 26.9%) were history of HF hospitalization, tricuspid annular plane systolic excursion (TAPSE) and 
angiotensin-converting-enzyme inhibitor (ACEI)-naive patients.
Conclusions. Treatment of chronic HFrEF patients with sacubitril/valsartan is safe and is associated with 
significant clinical and objective improvement. The non-survivors had more advanced HF, so the initiation 
and uptitration of sacubitril/valsartan should be done early.
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Introduction
The prevalence of heart failure (HF) rises exponentially 
and affects approx. 1–2% of the adult population; however, 
it can be as high as 10% in elderly patients.1–3 Patients with 
HF with reduced ejection fraction (HFrEF) constitute ap-
prox. 40–50% of all chronic HF patients and are broadly 
characterized by younger age, more prevalent coronary 
artery disease (CAD) and worse survival in comparison 
to HF with relatively preserved ejection fraction (EF).4 
On  the  other hand, the  population of  HFrEF patients 
is much better studied, and effective and proven thera-
pies have been successfully introduced over the last couple 
of decades, which have favorably improved the outcomes.4
Among effective therapies, a novel class of agents act-
ing simultaneously on the renin-angiotensin-aldosterone 
system (RAAS) and the  neutral endopeptidase system 
– angiotensin receptor neprilysin inhibitors (ARNI) – has 
shown promise for numerous HFrEF patients.5 In the land-
mark PARADIGM-HF study, ARNI was clearly superior 
to enalapril in improving the symptoms and prognosis for 
HF patients caused by ischemic or non-ischemic HFrEF.6 
So far, numerous papers that clearly confirmed the ben-
efits of sacubitril/valsartan (ARNI) in the various subgroups 
of HFrEF patients from different geographical settings have 
been published. Unfortunately, so far, sacubitril/valsartan 
is not reimbursed in Poland (unlike in other European and 
non-European countries) for HFrEF patients, which results 
in underutilization of this novel treatment in Polish pa-
tients. Consequently, the experience with ARNI is limited 
in Poland.
Therefore, this study aims to respond to the as-yet unmet 
clinical need to investigate the subject of clinical experi-
ence with sacubitril/valsartan in a mid-sized HFrEF cohort 
from 3 HF referral centers in central and southern Poland.
Material and methods
This observational multicenter study was conducted in 3 
clinical centers in Poland (Kraków, Łódź and Warszawa) 
specializing in HF. The study included 89 patients suffering 
from chronic HFrEF. The inclusion criteria were as follows: 
stable (defined as at least 4 weeks without HF exacerbation) 
and symptomatic HF categorized as NYHA (New York Heart 
 Association) class II–IV (ambulatory); left ventricular ejec-
tion fraction (LVEF) lower than or equal to 40%; and optimal 
treatment of HFrEF according to the guidelines of the Euro-
pean Society of Cardiology (ESC).4 The exclusion criteria were: 
hypotension (systolic blood pressure (SBP) <100 mm Hg), 
renal dysfunction with estimated glomerular filtration rate 
(eGFR) <30 mL/min/1.73 m2, hyperkalemia >5.4 mmol/L, 
history of angioedema, and thyroid dysfunction.
The  comprehensive analysis of  clinical, laboratory 
and echocardiographic parameters was performed and 
 included the following:
− age, gender, body mass index (BMI), and systolic (SBP) 
and diastolic (DBP) arterial blood pressure,
− coincidence of arterial hypertension, diabetes mellitus 
(DM), CAD, history of myocardial infarction, atrial fibril-
lation (AF), renal failure, chronic obstructive pulmonary 
diseases (COPD), cancer, and coronary interventions such 
as percutaneous coronary intervention (PCI) or coronary 
artery bypass graft (CABG);
− electrotherapy – cardiac resynchronization therapy 
(CRT-D, CRT-P) and implantable cardioverter defibrilla-
tor (ICD);
− HF etiology (ischemic compared to non-ischemic) and 
duration of HF;
− basic laboratory results, i.e., N-terminal prohormone 
B-type natriuretic peptide (NT-proBNP) and high-sensi-
tivity troponin T, creatinine with eGFR, and potassium 
level;
− electrocardiography (ECG) variables: heart rhythm 
and heart rate (HR), QRS duration;
− selected echocardiographic results, i.e., LVEF, end-
diastolic volume (EDV)/end-systolic volume (ESV) of left 
ventricle, right ventricular diameter (RVD), tricuspid an-
nular plane systolic excursion (TAPSE), pulmonary artery 
systolic pressure (PASP), volume of left atrium;
− drugs and doses of standard HFrEF therapy: angio-
tensin-converting-enzyme inhibitors (ACEI), angiotensin 
receptor blockers (ARB), β-blockers (BB), mineralocor-
ticoid receptor antagonist (MRA), ivabradine, diuretics, 
and digoxin;
− results of six-minute walking test (6MWT);
− MAGGIC (Meta-Analysis Global Group in Chronic 
Heart Failure) score.7
During a one-year follow-up, the following factors were 
analyzed: clinically important variables (NYHA class, arte-
rial blood pressure, HR, QRS duration, LVEF, NT-proBNP, 
6MWT, creatinine, and potassium level), and the compos-
ite endpoint (death and/or HF hospitalization).
The paper also includes an analysis of the sacubitril/
valsartan safety and tolerability profile.
Initial dose of sacubitril/valsartan and 
increase to the target maintenance dose
Patients enrolled in the study received a starting dose 
of sacubitril/valsartan as 1 tablet of 24/26 mg twice daily 
or 49/51 mg twice daily, as recommended.8 The sacubitril/
valsartan 24/26 mg initial dose was used in patients with 
SBP ≥ 100–110 mm Hg, in patients not currently taking 
ACE-I or ARB, or taking low doses of these medicinal 
products, and in patients with moderate renal impair-
ment (eGFR 30–60 mL/min/1.73 m2) or moderate hepatic 
insufficiency (Child–Pugh class B). Sacubitril/valsartan 
49/51 mg was used in patients with SBP > 110 mm Hg, 
and normal eGFR and serum potassium level. The dose 
was doubled at 2–4 weeks to the target dose of 1 tablet 
of 97/103 mg twice daily, as tolerated by the patient with 
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normal pressure tolerance, normal eGFR and normal se-
rum potassium level.
The  dose was temporarily reduced or  discontinued 
in  case of  symptomatic SBP  ≤  90  mm  Hg, hyperkale-
mia >5.4 mmol/L and worsening renal function defined 
as eGFR < 30 mL/min/1.73 m2. Patients received sacubitril/
valsartan at least 36 h after discontinuing ACE inhibitor 
therapy.
Statistical analysis
Quantitative variables are reported as mean and stan-
dard deviation (SD) or, for non-normally distributed vari-
ables, the median and interquartile range (IQR). Normal-
ity of the variables was verified using the Shapiro–Wilk 
normality test. For categorical variables, the  number 
of observations (N) with the corresponding percentage 
(%) is given.
To compare 2 independent groups, Student’s t-test for 
quantitative variables with normal distribution or the non-
parametric Mann–Whitney U test for non-normally dis-
tributed variables were used. To compare more than 2 
independent groups, analysis of variance (ANOVA, for 
normally distributed quantitative variables) or the Krus-
kal–Wallis test (if the distributions of variables were dif-
ferent from normal) with post hoc multiple comparisons 
(Tukey’s honest significant difference (HSD) test) was used.
For categorical variables, Pearson’s χ2 test, the maximum 
likelihood (ML) χ2 test or χ2 test with Yates’s correction 
was applied (regarding the expected counts in the con-
tingency tables).
The paired sample t-test (for normally distributed quan-
titative variables) or the nonparametric Wilcoxon signed-
rank test (for non-normally distributed quantitative vari-
ables) or the McNemar–Bowker test with correction for 
continuity (for categorical variables) was used to compare 
2 dependent groups (before and after the treatment).
Variables significant in  univariate comparisons 
at p < 0.05 were included in the multivariable stepwise 
logistic regression model to determine the independent 
risk factors of the composite endpoint.
Taking into account the  time to event (i.e., the  time 
to death, the composite endpoint), the Kaplan–Meier sur-
vival curves were determined. To compare 2 Kaplan–Meier 
curves, the log-rank test was applied. The Cox proportional 
hazards model was used to determine the independent risk 
factors of the composite endpoint.
The  results were considered statistically significant 
at p < 0.05. All the calculations were performed using 
the STATISTICA PL v. 13.3 package (StatSoft Inc., Tulsa, 
USA). The studied population was analyzed in relation 
to HF etiology: ischemic compared to non-ischemic and 
composite endpoint.
The study design was approved by the Bioethics Com-
mittee of the Jagiellonian University, Kraków, Poland (ap-
proval No. 1072.6120.55.2020).
Results
Table 1 shows the baseline characteristics of the total 
population and the analyzed groups of patients, divided 
according to HF etiology into ischemic HF (n = 42, 47%) 
and non-ischemic HF, caused mainly by dilated cardio-
myopathy (DCM), arrhythmias or primary valvular heart 
diseases. Patients with non-ischemic HF were younger, had 
shorter duration of HF, had more preserved renal function, 
larger left ventricles and lower EF, but they had higher low-
density lipoprotein (LDL) levels. The 2 groups did not dif-
fer in terms of baseline blood pressure, HR, NYHA class, 
number of comorbidities, NT-proBNP levels, or baseline 
HF medications.
For the total population, the comparison of clinically 
relevant parameters between baseline and at one-year as-
sessment is presented in Table 2. Overall, NYHA class, 
distance in  the  6MWT, LVEF, and NT-proBNP levels 
significantly improved after a year of treatment. Further, 
we observed significant reductions in both SBP and DBP, 
HR, and QRS complex width. Finally, potassium levels and 
creatinine remained unchanged.
After a year, 20% (n = 15) of patients were treated with 
24/26 mg of sacubitril/valsartan twice daily, 28% (n = 20) 
received 49/51 mg twice daily and 52% (n = 38) received 
the maximum dose. An adverse event in the form of hy-
potension, hyperkalemia or worsening renal function oc-
curred in 17.8% (n = 16), 5.6% (n = 5) and 4.5% (n = 4) 
of patients, respectively.
In 12% (n = 11) of patients, the sacubitril/valsartan dose 
was reduced during the study. Hypotension was the cause 
of the dose reduction in 10 patients (11%) and the decrease 
of eGFR in 1 patient (1%). Sacubitril/valsartan was discon-
tinued in 10% (n = 9) and hypotension was the main cause 
(4.5%, n = 4), in 1 patient at dose 49/51 mg twice daily and 
in 3 patients at 97/103 mg twice daily. One patient (1%) 
discontinued treatment due to worsening renal function 
(drug dose 49/51 mg twice daily) and 4 patients (4.5%) due 
to hyperkalemia – 1 patient at a dose of 49/51 mg twice 
daily and 3 patients at a dose of 97/103 mg twice daily.
The population that received the highest dose of sacu-
bitril/valsartan compared to patients receiving the low-
est or intermediate dose had the shortest history of HF 
(respectively 70  months vs 157  months vs 81  months; 
p = 0.001), the lowest number of visits to primary care 
(4 vs 6 vs 4.5; p = 0.005), the highest SBP (respectively 
123 mm Hg vs 108 mm Hg vs 113 mm Hg; p = 0.002) and 
DBP (75 mm Hg vs 66 mm Hg vs 72 mm Hg; p = 0.002), and 
the lowest initial NT-proBNP (respectively 2620 pg/mL vs 
4446 pg/mL vs 4417 pg/mL; p = 0.003).
During a  one-year follow-up, 8  patients died (8.9%); 
the  mean time to  death was 5.88  ±4.16  months. One 
of non-survivors discontinued the treatment of sacubi-
tril/valsartan 1 month before death. The MAGGIC score 
in the whole group was 24 ±5.4. This implies one-year 
probability of death of approx. 14.7%, which is much higher 
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Table 1. Baseline characteristics and related to etiology. Data is presented as mean ± standard deviation (SD), median (interquartile range – IQR) or number 
(percentage) in variables with non-parametric distribution
Parameter Total population, n = 89 Non-ischemic HF, n = 47 Ischemic HF, n = 42 p-value
Age [years] 62 (56–68) 59 (43–66) 63 (59–72) 0.002
Male sex, n (%) 73 (82) 34 (72.3) 39 (92.9) 0.025
BMI [kg/m2] 27.34 ±4/6 26.95 ±4.26 27.79 ±4.91 0.39
HF duration [months] 72 (32–133) 50.5 (12–120) 85.5 (42–143) 0.03
SBP [mm Hg] 116.9 ±14.1 114.94 ±14.51 119.1 ±13.5 0.17
DBP [mm Hg] 72.5 ±8.5 72.30 ±8.19 72.76 ±8.94 0.85
NYHA class 3 (3–3) 3 (3–3) 3 (3–3) 0.98
Hospitalization HF, n (%) 48 (54) 23 (48.9) 25 (59.5) 0.32
Atrial fibrillation, n (%) 36 (40) 18 (38.3) 18 (42.9) 0.66
Diabetes, n (%) 36 (40) 19 (40.4) 17 (40.5) 0.99
Hypertension, n (%) 52 (58) 23 (48.9) 29 (69) 0.055
Dyslipidemia, n (%) 49 (55) 22 (46.8) 27 (64.3) 0.09
COPD, n (%) 8 (9) 2 (4.3) 6 (14.3) 0.2
NT-proBNP [pg/mL] 2600 (914–4783) 2858 (1017–4967) 2186 (797–4783) 0.73
Hemoglobin [g/dL] 13.8 ±1.88 13.97 ±2.13 13.6 ±1.6 0.4
Na [mmol/L] 139.9 ±2.78 140.1 ±2.65 139.7 ±2.94 0.5
K [mmol/L] 4.49 ±0.39 4.46 ±0.37 4.52 ±0.41 0.53
Creatinine [μmol/L] 94.6 (81–113) 91 (77–108) 105.1 (85–129) 0.03
eGFR [mL/min/1.73 m2] 70.9 ±22.7 76.22 ±22.36 65.1 ±21.9 0.02
BUN [mmol/L] 12.3 (8–17.5) 13.2 (7.95–19.8) 13.4 (6.7–26.0) 0.69
Glucose [mmol/L] 5.7 (5.1–6.8) 5.8 (5–7.1) 5.5 (5.1–6.6) 0.45
LDL [mmol/L] 2.23 ±0.88 2.43 ±0.97 2.02 ±0.72 0.04
Bilirubin [mg/dL] 20.7 (14.3–39.4) 17.3 (13–37.9) 26.7 (17–47.6) 0.17
LVD [mm] 66 (60–72) 68.66 ±9.57 63.7 ±9.1 0.014
EDV LV [mL] 221.2 ±90.3 221.9 ±106.1 220.1 ±65.1 0.69
ESV LV [mL] 171.2 ±81.4 175.55 ±96.24 165 ±55.1 0.66
RVD prox. [mm] 34.9 ±6.02 34.87 ±6.5 35.1 ±5.6 0.88
LA vol. [mL] 133.6 ±51.4 129.25 ±45.28 136.7 ±56.2 0.8
LVEF [%] 23.6 ±6.7 22.25 ±6.85 25.05 ±6.24 0.02
TAPSE [mm] 16.7 ±4.2 16.5 ±3.96 16.9 ±4.5 0.6
PASP [mm Hg] 43.3 ±13.19 42.5 ±13.9 44.1 ±12.6 0.69
6MWT distance [m] 353.2 ±99.6 357.64 ±96.23 347.9 ±105.6 0.73
HR [bpm] 74.4 ±7.4 77.7 ±12.9 75.9 ±8.5 0.86
QRS duration [ms] 114 (102–140) 110 (100–140) 120 (108–128.5) 0.83
Prior ACEI/ARB, n (%) 87 (98) 45 (95.7) 42 (100) 0.98
β-blockers, n (%) 87 (98) 46 (97.9) 41 (97.6) 0.98
MRA, n (%) 80 (90) 43 (91.5) 37 (88.1) 0.86
Ivabradine, n (%) 16 (18) 7 (15.2) 9 (21.4) 0.45
Loop diuretic, n (%) 73 (85) 37 (87.2) 36 (87.8) 0.67
Digoxin, n (%) 16 (18) 10 (21.3) 6 (14.3) 0.39
MAGGIC score 24 ±5.4 23.1 ±4.7 25 ±6.04 0.1
ICD at baseline, n (%) 36 (40) 14 (40.4) 22 (52.4) 0.26
CRT at baseline, n (%) 15 (17) 6 (12.8) 9 (21.4) 0.28
ACEI – angiotensin-converting-enzyme inhibitors; ARB – angiotensin receptor blockers, BMI – body mass index; BUN – blood urea nitrogen; COPD – chronic 
obstructive pulmonary disease; CRT – cardiac resynchronization therapy; DBP – diastolic blood pressure; DM – diabetes mellitus; eGFR – estimated 
glomerular filtration rate; HF – heart failure; HR – heart rate; ICD – implantable cardioverter defibrillator; LDL – low-density lipoprotein; LVD – left ventricle 
diameter; LVEF – left ventricle ejection fraction; MRA – mineralocorticoid antagonist, NT-proBNP – N-terminal prohormone B-type natriuretic peptide; 
SBP – systolic blood pressure; EDV LV – end diastolic volume – left ventricle; ESV LV – end systolic volume – left ventricle; RVD – reference vessel diameter; 
LA vol. – left atrial volume; TAPSE – tricuspid annular plane systolic excursion; PASP – pulmonary artery systolic pressure; 6MWT – six-minute walk test; 
MAGGIC – Meta-Analysis Global Group in Chronic Heart Failure.
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than the observed one-year mortality in the studied pop-
ulation. Furthermore, the MAGGIC score was similar 
in non-survivors and survivors (25.7 ±5.7 vs 23.9 ±5.3; 
p = 0.37). The Kaplan–Meier curves for death in the total 
population and related to HF etiology (p > 0.05) is pre-
sented in Fig. 1 and Fig. 2.
During a one-year follow-up, in 24 patients (26.9%), the com-
posite endpoint was reported. These patients had a higher 
level of NT-proBNP (4488.5 [2599–7129.5] pg/mL vs 2049.5 
[746–3889.5] pg/mL, p = 0.002), more HF hospitalizations 
in the last 12 months (median 2 [1–3] vs 0 [0–1]; p = 0.0001) 
and lower SBP (111.3 ±12.5 mm Hg vs 118.5 ±13.9 mm Hg; 
p  =  0.028), distance in  6MWT (301.6  ±101.3  m  vs 
367.1 ±95.3 m; p = 0.046) and TAPSE (16.6 ±2.65 mm vs 
17.5 ±4.46 mm; p = 0.004). These parameters indicated more 
advanced HF in these patients. In analysis regarding HF eti-
ology, the composite endpoint occurred in 11 patients with 
ischemic etiology and in 13 with non-ischemic (p = 0.83). 
The time to composite endpoint was 3.32 ±2.03 months 
for ischemic etiology of HF and 4.44 ±3.95 months for non-
ischemic etiology. The multivariable analysis revealed 3 in-
dependent variables for risk of composite endpoint (Table 3): 
history of HF hospitalization, TAPSE and ACEI treatment. 
According to ANOVA analysis, only RVD in ischemic eti-
ology of HF was significant for risk of composite endpoint 
(p = 0.0452) (Fig. 3).
Table 2. Comparison of clinically important variables after 1 year of treatment with sacubitril/valsartan. Data is presented as mean ± standard deviation (SD), 
median (interquartile range – IQR) or number (percentage) in variables with non-parametric distribution
Parameter Baseline (n = 73) After 1 year of treatment (n = 73) p-value
NYHA class 3 (3–3) 2 (1–2) <0.001
SBP [mm Hg] 117.2 ±13.9 109.9 ±13.4 <0.001
DBP [mm Hg] 72.7 ±8.3 68.3 ±9.9 <0.001
HR [bpm] 76 (70–80) 75 (68–79) <0.005
QRS duration [ms] 115 (102–140) 110 (107–135) <0.01
LVEF [%] 23.8 ±6.5 27 ±6.4 <0.001
K [mmol/L] 4.4 ±0.4 4.5 ±0.38 0.88
Creatinine [μmol/L] 95 (81–113) 101 (86–115) 0.21
NT-proBNP [pg/mL] 2600 (969.2–4542) 1628 (679–3009) <0.001
6MWT distance [m] 337.3 ±96.9 423.8 ±71.9 <0.001
DBP – diastolic blood pressure; HR – heart rate; LVEF – left ventricle ejection fraction; NT-proBNP – N-terminal prohormone B-type natriuretic peptide; 
SBP – systolic blood pressure; NYHA – New York Heart Association; 6MWT – six-minute walk test.
Fig. 1. Kaplan–Meier curve 
of death during 1 year 
in the studied population
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Discussion
We present the first real-life observation of one-year 
treatment with sacubitril/valsartan in  a  Polish HFrEF 
population. The studied population represents a typical 
HFrEF cohort. Of note, we report a relatively high propor-
tion of DCM patients (52.5% vs 40% in PARADIGM-HF), 
lower EF (our population – 23.5 ±8.9 vs PARADIGM-HF 
–  29.6  ±6.1% and higher levels of  NT-proBNP (ours 
– 2600 pg/mL vs 1631 pg/mL); such results reflect more 
advanced HFrEF and probably the fact that our centers 
serve as regional referral centers for more sophisticated 
diagnostic work-up (e.g., referrals for heart transplant 
or mechanical circulatory support in DCM or hemody-
namically compromised patients).6 More advanced HFrEF 
in our study as well as in the first report on Polish patients 
Fig. 3. Two-way ANOVA results 
for RVD prox. (LAX) at baseline 
– interaction effect between 
etiology and composite endpoint 
(marginal means ± standard error 
(SE); p = 0.0453)
Fig. 2. Kaplan–Meier curve 
of composite endpoint (death 
and/or HF hospitalization) during 
1 year in the studied population 
related to etiology of HF
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from 20189 in comparison to the PARADIGM-HF baseline 
characteristics probably results from the fact that tertiary 
cardiac centers, with the greatest HF expertise, decided 
to start ARNI treatment in Poland.
Overall, we  observed very favorable outcomes af-
ter 1 year of treatment with sacubitril/valsartan, which 
was consistent in various parameters of clinical interest, 
such as improvements in NYHA class, EF and distance 
in 6MWT, as well as substantial reduction of NT-proBNP 
levels. Reassuringly, and similarly as in other ARNI trials, 
including PARADIGM-HF, we did not observe safety issues 
with ARNI, i.e., the substantial reduction of both SBP and 
DBP was asymptomatic in the great majority of patients, 
and the much feared worsening of renal function did not 
occur (stable levels of creatinine and potassium).
Although the study population was relatively small com-
pared to large multi-center randomized controlled trials 
or ESC-initiated registries, we report here a real-life and 
probably the largest population of HFrEF patients treated 
with ARNI in Poland. For the first time we report a one-year 
follow-up, which reassuringly is similar to other studied 
populations in real-world studies.10–14 This and other stud-
ies showed a clear benefit of sacubitril/valsartan treatment 
of HFrEF patients, which directly translates into improve-
ment in clinical, echocardiographic and laboratory indices. 
We sincerely hope that the increasing number of papers 
showing effectiveness of  sacubitril/valsartan will pave 
the way for widespread utilization of this treatment in Polish 
patients, which currently is limited due to non-medical rea-
sons (unbearable financial cost for the majority of patients).
Sacubitril/valsartan is recommended in the ESC guide-
lines for further reduction in the risk of hospitalization 
or death in patients with HFrEF if  symptoms continue 
despite optimal treatment with ACEI/ARB, β-blockers 
and mineralocorticoid antagonists. At baseline, the stud-
ied population was optimally treated in terms of the class 
of the standard therapy of ACEI/ARB, BB and MRA (Table 1). 
After 1 year, only ivabradine was more frequently used 
(from 18% at baseline to 29%, p = 0.077). However, the tar-
get doses of 50% or more were obtained for BB from 66% 
at baseline to 63% after a year, for MRA it was stable at 77%, 
and for ivabradine it varied from 54% at baseline to 69%. 
It should be emphasized that in comparison to the obser-
vational QUALIFY registry for ambulatory Polish patients 
suffering from chronic HF,15 both prescription of standard 
HFrEF therapy and ivabradine and the proportion of target 
doses are higher in our study, but still suboptimal.
For ARNI, the TITRATION study indicated that 75.9% 
of randomized patients achieved ‘treatment success’, de-
fined as achieving and maintaining a dose of sacubitril/
valsartan of 97/103 mg twice daily without any dose inter-
ruption/down-titration over 12 weeks.16 In our study, after 
a year, 80% of patients were on 50% or more of the target 
dose of sacubitril/valsartan (49/51 mg or 97/103 mg twice 
daily). In the PROVE-HF study, after a year of treatment, 
65% of patients received the maximum dose of sacubitril/
valsartan, 21% received a moderate dose and 14% received 
the lowest dose.17 In our study, the involvement of indi-
vidual doses represents 52%, 28% and 20%, respectively, 
and was comparable in the moderate dose (49/51 mg) 
to the PROVE-HF study.17 More frequent use of  lower 
doses in our population in relation to the PROVE-HF 
populations may have resulted from lower SBP and DBP 
(116 ±14 mm Hg and 72 ±8 mm Hg vs 124.5 ±16 mm Hg 
and 76 ±10.3 mm Hg, respectively) and more advanced HF 
(NT-proBNP 2600 pg/mL vs 816 pg/mL, respectively).17
In our study, patients treated with the maximum target 
dose constituted the least burdened population at base-
line (eGFR 75.91 mL/min/1.73 m2, SBP 123 mm Hg). It al-
lowed us to use the maximum doses, which further en-
hanced the therapeutic effects in comparison to the groups 
at lower doses. Thus, the earlier incorporation of the drug, 
as well as treatment with higher doses, has a beneficial ef-
fect on the prognosis of patients with HFrEF.
Hypotension, hyperkalemia and worsening renal func-
tion were the most frequent adverse events in our and 
the PROVE-HF study. Hypotension was observed with 
a comparable frequency in the studied population and 
in the PROVE-HF study (17.8% compared to 17.6%, respec-
tively).17 It should be emphasized that hyperkalemia and 
worsening renal function were less frequently observed 
in our study than in the PROVE-HF study (5.6% and 4.5% 
compared to 13.2% and 12.3%).17 Moreover, no statisti-
cally significant differences were observed in potassium 
and creatinine values in our population at the beginning 
of the study and after 1 year. However, the most common 
reasons for discontinuation of therapy were hypotension, 
hyperkalemia and worsening kidney function in both our 
study and PARADIGM-HF, and at a similar level (11% com-
pared to 11.4%, respectively).6
Table 3. Results of multivariable analysis for the composite endpoint
Variable p-value OR 95% CI for OR
History of HF hospitalization 0.001 2.194 1.397 3.448
TAPSE at baseline 0.035 0.826 0.691 0.987
ACEI before ARNI 0.011 0.176 0.046 0.672
Intercept 0.144 x x x
OR – odds ratio; 95% CI – 95% confidence interval; HF – heart failure; TAPSE – tricuspid annular plane systolic excursion; ACEI – angiotensin-converting-
enzyme inhibitor; ARNI – angiotensin receptor neprilysin inhibitors.
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At baseline, a little more than half of the population had 
devices (ICD or CRT in 57%), and in the one-year follow-
up, 14 patients subsequently received an ICD (8) or CRT 
(6). That is even more than in the QUALIFY population 
(28.7%); however, there is still a  large need for invasive 
procedures in the HFrEF population in our country.
In  the  studied population, AF was highly prevalent 
(36/89 patients), including 18 (38.3%) out of 47 non-isch-
emic HF and 18 (42.9%) out of 42 ischemic HF patients. 
In  the  AF population, 22 (61%) had severe reduction 
in LVEF ≤ 25% and 16 (44%) were older than 65. Regard-
less of HF etiology, there were no differences of the drug 
therapy, including β-blockers. Digoxin was used in 16 pa-
tients (18%). During the one-year observation, no ablation 
procedure was performed. 
The  mean HR in  the  AF group was 81 bpm, while 
in the sinus rhythm group it was 75 bpm. At baseline, 35 pa-
tients with AF (97%) were taking β-blockers and after 1 year 
– all patients; however, 13 (36%) were treated less than 50% 
of the target β-blockers. After 1 year of sacubitril/valsartan 
treatment, a change in β-blockers treatment was observed 
in 5 patients. Three patients had reduced their β-blockers 
dose (bradyarrhythmia), 1 discontinued the  treatment 
due to peripheral artery disease (PAD), and 1 patient had 
increased the dose above 50% of the target dose. During 
the one-year follow-up, in 13 AF patients (36%), the com-
posite endpoint was reported, including 3 deaths (8%).
In the studied population, patients who died (9.09%) had 
a higher level of NT-proBNP (3337 [3243–5631] pg/mL vs 
1337.5 [653.5–2231.5] pg/mL; p = 0.002) and blood urea ni-
trogen – BUN (27 [21–34] mmol/L vs 10.2 [6.7–21] mmol/L; 
p = 0.0056), lower distance in the 6MWT (273.2 ±105.1 m vs 
431.3 ±85.5 m; p = 0.039), and a larger RVD in echocar-
diography measured in the parasternal longitudinal axis 
(40.86 ±4.71 mm vs 34.3 ±5.85 mm, p = 0.0055). These 
parameters indicated the more advanced HF in the non-
survival population. The integer risk score of approx. 24 lo-
cates our population between the 3rd and 4th risk group with 
estimated one-year probability of death between 13.4% 
and 16%.7 Thus, the MAGGIC score clearly overestimated 
the one-year probability of death in our population (true 
one-year mortality in our population – 9.09% compared 
to estimated one-year mortality – 14.7%).7 Apart from nu-
merous factors that may be responsible for this inaccuracy, 
such as the relatively small population size (which may dis-
tort statistical calculations), the majority of patients with 
non-ischemic HF (with usually worse prognosis in isch-
emic HF), younger age of our population than the original 
MAGGIC cohort, etc., the favorable effect of sacubitril/
valsartan should also be taken into account.
The composite endpoint (cardiovascular mortality and 
hospitalization) after a year occurred in 17.3% in the ESC-
EORP-HFA Heart Failure Long-Term Registry,18 and in our 
study in 27.3%. However, it  should be pointed out that 
the components of the composite endpoint in our study 
are different (death and HF hospitalization). It should also 
be noted that there were differences in hospitalization due 
to decompensation, in 13% of patients in the abovemen-
tioned Registry compared to 27.3% in the present popula-
tion. It seems that the increased number of hospitalizations 
in our study is a result of more advanced HF in the studied 
population and the inadequately organized outpatient care 
in our country (the routine treatment of patients with de-
compensation of HF in hospital). Mortality in our popula-
tion was 9.09% and was higher than in the Registry after 
a year of treatment of sacubitril/valsartan, which was 8.8%.18 
Ischemic etiology (5.6%, n = 5) was a more frequent cause 
of death in our population than non-ischemic etiology (3.3%, 
n = 3), which is consistent with other studies that indicate 
a worse prognosis for patients with ischemic HF etiology.
From multivariable analysis independent variables for 
risk of composite endpoint were revealed (history of HF 
hospitalization, TAPSE and ACEI treatment at baseline), 
which indicate more advanced HF and worse prognosis 
in ACEI-naive patients, and according to ANOVA analy-
sis, in ischemic HF only the RVD was important for risk 
of composite endpoint. It  is well known that the right 
ventricle dilates in end-stage disease, and is a predictor 
of poor outcome in HF.19,20 However, recently Correale 
et al. observed in a real-life population with chronic HFrEF 
improvement of right ventricular function under sacubi-
tril/valsartan treatment.21
Limitations
There are several potential limitations to  the  pres-
ent study that should be acknowledged. Firstly, the size 
of the study population is small; however, ARNI treatment 
in Poland in not reimbursed, which results in unbearable 
cost of treatment for the majority of patients in need. Sec-
ondly, the fact that patients were recruited in the referral 
centers may slightly distort the typical HFrEF patients 
in Poland, which in fact may be less severe. Thirdly, the ob-
servation period of 12 months seems to be relatively short; 
nevertheless, the composite endpoint occurred in more 
than a quarter of patients. Fourthly, the mean age of our 
study population is at least a decade younger than a typi-
cal (real-world) HF cohort. Fifthly, a great majority of our 
patients have long-standing HF. Consequently, new-on-
set (or de novo) HF patients are under-represented. Also, 
this was an observational study without a control group. 
The lack of direct His bundle pacing in our patients with 
chronic AF, which is more and more widely used in this 
group of patients,22 may also be considered as a limitation 
of our work.
Conclusions
In summary, we present the first one-year observation 
of real-life HFrEF Polish patients treated with sacubitril/
valsartan with clinical improvement and good tolerability. 
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We confirmed that non-survivors had more advanced HF, 
so the initiation and uptitration of sacubitril/valsartan 
should be performed early in HFrEF.
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